BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical is expected to have a positive outlook due to their expanding pipeline of treatments in development, successful track record of developing treatments for rare genetic disorders, and recent settlement with Ascendis, which brings in significant economics through 2030. Despite market share loss risk, their continued integration of Amicus and success in pipeline development, along with the recent acquisition of Alesta, should generate strong returns for investors. While there are risks to consider, such as potential switching to competitors and lack of efficacy data for newly acquired assets, overall BioMarin remains a strong investment opportunity with a target price of $90 in the next 12 months.

BioMarin Pharmaceutical is currently facing challenges with the approval of its enzyme replacement therapy, ALE1, for adult-onset hypophosphatasia (HPP). This is due to the regulatory uncertainty surrounding the effectiveness of their previous drug, Strensiq, which was approved for pediatric-onset HPP. Additionally, with only one development program and 44% of the maximum deal value contingent on future development and approval milestones, BioMarin's financials may be negatively impacted in the long-term. Furthermore, the lack of employees transferring to BioMarin indicates that they are not acquiring a strong operating R&D platform, potentially affecting their ability to bring new treatments to market in the future.